CFT7455: Present Phase 1 dose escalation data from the Phase 1/2 clinical trial of Arm B1, evaluating CFT7455 as a monotherapy in MM, in the second half of 2023. CFT8634: Present Phase 1 dose escalation data from the Phase 1/2 clinical trial for synovial sarcoma and SMARCB1-null solid tumors in the second half of 2023.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CCCC:
- C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
- C4 Therapeutics price target lowered to $20 from $22 at UBS
- C4 Therapeutics announces inducement grants under Nasdaq listing rule
- C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- C4 Therapeutics’ FDA clearance of CFT8919 IND as expected, says Brookline
